These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25255732)

  • 1. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
    Limmroth V; Gerbershagen K
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
    Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
    Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex).
    Freedman SM; Cox D; Rosebrough T
    J Neurosci Nurs; 2008 Dec; 40(6):350-5. PubMed ID: 19170302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
    BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
    Wray S; Hayward B; Dangond F; Singer B
    Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
    Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
    BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
    Lampl C; You X; Limmroth V
    Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
    Wray S; Armstrong R; Herrman C; Calkwood J; Cascione M; Watsky E; Hayward B; Mercer B; Dangond F
    Expert Opin Drug Deliv; 2011 Dec; 8(12):1543-53. PubMed ID: 22032264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.
    Mohr DC; Cox D; Merluzzi N
    Mult Scler; 2005 Apr; 11(2):182-5. PubMed ID: 15794392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
    Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
    Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
    Lugaresi A
    Expert Opin Drug Deliv; 2013 Feb; 10(2):273-83. PubMed ID: 23252744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study.
    Zecca C; Pavelek Z; Přikrylová K; Ghielmetti M; Beeler A; Gobbi C
    Mult Scler Relat Disord; 2019 May; 30():104-109. PubMed ID: 30763907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
    Clanet M; Kappos L; Hartung HP; Hohlfeld R;
    Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.